secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-06-11T21:06:44+00:00
Accession:  0001193125-26-267862
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics stockholders approve reverse stock split at 1:10 to 1:100 ratio
--------------------------------------------------------------------------------

- Reverse stock split approved with 4,715,574 for, 1,517,896 against, 21,866 abstentions.
- Board authorized to determine timing and exact ratio within 1-for-10 to 1-for-100 range.
- Class I director June Bray elected with 2,430,964 votes for, 216,735 withheld; 3,607,640 broker non-votes.
- BDO USA, P.C. ratified as independent auditor for FY2026 with 6,080,608 votes for.
- Advisory vote on executive compensation approved with 2,504,778 for, 116,876 against, 26,044 abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/0001193125-26-267862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/d124733d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-267862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer